Bloomage Biotechnology

Bloomage Biotechnology, founded in April 2006 and based in the Cayman Islands, operates in the biomedicine sector, focusing on the production and distribution of hyaluronic acid (HA) and its derivatives. The company primarily generates revenue through two segments: HA raw materials and HA end products. The raw materials segment offers HA in three grades—medicine, cosmetic, and food—produced using bio-fermentation technology. The end products segment includes medical skincare items, bone products for intra-articular injection, and medical beauty devices. With a significant portion of its revenue derived from China, Bloomage Biotechnology is committed to advancing its offerings in the field of biomedicine.